The perplexing role of immuno-oncology drugs in osteosarcoma.
Loading...
Embargo End Date
ICR Authors
Authors
Smrke, A
Tam, YB
Anderson, PM
Jones, RL
Huang, PH
Tam, YB
Anderson, PM
Jones, RL
Huang, PH
Document Type
Journal Article
Date
2021-12-01
Date Accepted
2021-10-19
Abstract
Osteosarcoma is a rare, primary tumour of bone. Curative treatment consists of multi-agent chemotherapy and complete surgical resection. Despite the use of multi-agent chemotherapy, the risk of recurrence is high. Survival outcomes for patients with osteosarcoma have not changed since the 1980's. Based on biologic rationale, there has been interest in adding immunotherapies to upfront curative intent chemotherapy, including mifamurtide (a macrophage activator) and interferon. However, results to date have been disappointing. In the metastatic setting, checkpoint inhibitors alone have not proven effective. Ongoing translational work is needed to further understand which patients may benefit from immune-oncology approaches with standard cytotoxic chemotherapy.
Citation
Journal of bone oncology, 2021, 31 pp. 100400 - ?
Source Title
Publisher
ELSEVIER
ISSN
2212-1366
eISSN
2212-1374
2212-1374
2212-1374
Collections
Research Team
Molecular and Systems Oncology